Cancer Immunity, Vol. 5, p. 8 (6 June 2005)
نویسندگان
چکیده
A single tumor contains a heterogeneous population of cancer cells. Some cancer cells express antigens and are susceptible to specific CTLs. However, other cancer cells are antigen-loss variants (ALVs) that escape these CTLs because they express little or no antigen. Here, we show that antigen-specific T cells can eliminate ALVs when the parental population expresses a model gp33 antigen (KAVYNFATM) at a level sufficient to be locally cross-presented by the nonmalignant stromal cells. That is, the ALVs are eliminated as bystanders because the stroma is destroyed. ALVs escape bystander killing when the bone marrow-derived and/or non-bone marrow-derived stroma does not express the appropriate MHC or when the amount of antigen is too low for effective cross-presentation. The rapid destruction of the stroma, including bone marrow-derived as well as sessile components, and of the parental cancer cells, may be essential for the complete rejection of established tumors by preventing variant escape.
منابع مشابه
Cancer Immunity (27 March 2008) Vol. 8, p. 6
1Multidisciplinary Oncology Center, University of Lausanne Hospitals (CHUV), Lausanne, Switzerland 2Department of Radio-Oncology, CHUV, Lausanne, Switzerland 3Division of Experimental Oncology, Multidisciplinary Oncology Center, CHUV, Lausanne, Switzerland 4Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland 5Department of Pathology...
متن کاملCancer Immunity (22 March 2006) Vol. 6, p. 6
1Multidisciplinary Oncology Centre (CePO), Lausanne, Switzerland 2Ludwig Institute for Cancer Research (LICR), Lausanne Branch, Lausanne, Switzerland 3Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland 4National Centre for Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Swi...
متن کاملCancer Immunity (24 April 2008) Vol. 8, p. 8
1Department of Microbiology and Immunology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, TX, USA 2Division of Hematology & Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, TX, USA 3Kiromic Inc., Lubbock, TX, USA 4Norris Comprehensive Cancer Center and Departments of Mo...
متن کاملCancer Immunity (5 June 2009) Vol. 9, p. 5
1Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, New York, NY, USA 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 3Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 4Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New Yor...
متن کاملCancer Immunity (21 April 2006) Vol. 6, p. 8
1Flaherty Comparative Oncology Laboratory, Donaldson-Atwood Cancer Clinic, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA 2Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA 3Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005